About ventyx biosciences inc. - VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
VTYX At a Glance
Ventyx Biosciences, Inc.
12790 El Camino Real
San Diego, California 92130
| Phone | 1-760-593-4832 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -192,962,000.00 | |
| Sector | Health Technology | Employees | 80 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
VTYX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.60 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.465 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.131 |
VTYX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,412,025.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VTYX Liquidity
| Current Ratio | 11.873 |
| Quick Ratio | 11.873 |
| Cash Ratio | 11.328 |
VTYX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -59.229 |
| Return on Equity | -64.555 |
| Return on Total Capital | -75.25 |
| Return on Invested Capital | -63.218 |
VTYX Capital Structure
| Total Debt to Total Equity | 5.127 |
| Total Debt to Total Capital | 4.877 |
| Total Debt to Total Assets | 4.464 |
| Long-Term Debt to Equity | 4.717 |
| Long-Term Debt to Total Capital | 4.487 |